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The Kidd blood group system has been recognized as clinically 
important in red blood cell (RBC) serology since its identification 
in 1951. Forty years later, the JK glycoprotein was determined to 
be a product of SCL14A1 and was identical to the urea transport 
protein UT-B produced by HUT11A. The functional role of the 
protein as a urea transporter in RBCs and kidney has been well 
documented. The polymorphism responsible for the antithetical 
antigens Jka and Jkb was identified in 1994 as c.838G>A (p. 
Asp280Asn). Recent discoveries have expanded the system 
to include 23 variant alleles recognized by the International 
Society of Blood Transfusion that silence the protein expression 
and 7 variant alleles presumably producing weak or partial JK 
antigens. Null phenotypes have been identified in individuals 
of several populations including those of African, Indian, and 
Chinese decent, in addition to the well-documented findings in 
the Polynesian and Finnish populations. This review will examine 
the historical information about the antigens and antibodies of 
the JK system as well as catalog the variations of the JK gene. 
Immunohematology 2015;31:29–35.
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The Kidd blood group system (ISBT009) was the ninth 
blood group system identified. It was described in 1951 when 
an unknown antibody detected in the plasma of the propositus, 
Mrs. Kidd, caused hemolytic disease of the fetus and newborn 
(HDFN) in her infant son.1 His initials, JK, became the symbol 
that now represents this blood group system. The antithetical 
antigen, Jkb, was identified in 1953 when investigation of a 
transfusion reaction identified a new antibody.2 Discovery of 
the Jk(a–b–) phenotype followed in 1959.3 It is of interesting 
historical note that Dr. Mary Crawford, pediatrician and blood 
group serologist, discovered inheritance patterns in her family 
that suggested a silent JK allele while investigating her own 
Lu(a–b–) phenotype.4 Basic characteristics of the antigens 
and antibodies of this blood group system have been well 
established; however, much information has been obtained 
from molecular analysis of the JK protein.
Antigens and Inheritance
The JK blood group system consists of three antigens: 
Jka, Jkb, and Jk3. Jka and Jkb are inherited as codominant 
autosomal characteristics and are commonly found on red 
blood cells (RBCs) of most population groups.5 The three 
resulting phenotypes, however, exhibit varying frequencies 
among different population groups (Table 1). Jk3 has a very 
high prevalence and is found on all RBCs carrying either Jka 
or Jkb. The null phenotype, Jk(a–b–), identifies those RBCs 
that are Jk:–3. This phenotype occurs rarely, but has a greater 
frequency in individuals of Polynesian or Finnish descent upon 
inheritance of two silent alleles. The phenotype frequency in 
Polynesian populations is 0.1–1.4 percent, with frequency 
variations seen in different Polynesian tribes.6 In Finns, the 
Jk(a–b–) phenotype frequency is approximately 0.03 percent.7 
A second mechanism for the Jk(a–b–) phenotype is the 
inheritance of a dominant suppressor gene that leads to the 
apparent lack of JK antigens on the cell surface.8 In actuality, 
small amounts of Jka, Jkb, and Jk3 can be demonstrated when 
sensitive methods such as adsorption/elution are used. The 
suppressor null phenotype is designated In(Jk) and has been 
identified in two families of Japanese ancestry.
The JK antigens have been detected on fetal RBCs as early 
as 7–11 weeks’ gestation and are fully developed at birth.9 The 
Kidd antigen density has been shown to be approximately 
14,000 copies per cell as determined on Jk(a+b–) RBCs.10 
The antigens are not destroyed by treatment with proteolytic 
enzymes or sulfhydryl compounds. Variations in the 
expression of both Jka and Jkb have been described and will be 
discussed in further detail subsequently.
Genetics and Antigen Biochemistry
The gene encoding the JK glycoprotein, SLC14A1, is a 
member of the solute carrier family of genes. It is located on 
the long arm of chromosome 18 (18q11-q12) and is organized 
Table 1. Phenotypes in the Kidd blood group system
Incidence (%)
Phenotype White Black Asian
Jk(a+b–), Jk:3 26 52 23
Jk(a+b+), Jk:3 50 40 50
Jk(a–b+), Jk:3 24 8 27
Jk(a–b–), Jk:–3 Rare Rare Rare except 
Polynesians (0.9)
Modified from Fung et al.5
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into 11 exons. Exons 1–3 are not translated; exons 4–11 code 
for the mature JK glycoprotein.11,12
The human erythrocyte urea transport gene, HUT11, was 
identified in 199413 and later was assigned to the same position 
on chromosome 18 as the JK blood group locus.14 The encoded 
protein was demonstrated on all RBCs except Jk(a–b–) cells, a 
finding that linked the urea transport protein to the JK locus. 
Subsequently, it was identified that JK renamed SLC14A1, 
encoded for a related but slightly different polypeptide 
HUT11A.15 These discoveries resulted in an understanding of 
the functional aspects of the Kidd antigens.
The mature glycoprotein resulting from JK contains 389 
amino acids with a molecular weight of 45 kDa. Hydrophobicity 
studies predict that the protein is organized into five 
extracellular loops with 10 membrane-spanning regions13,16 
(Fig. 1). The third extracellular loop is significantly larger 
than the other four and contains the protein’s only external 
glycosylation site at amino acid position 211. This N-linked 
sugar chain has been shown to also carry ABO antigens.16 The 
N-terminal and C-terminal regions of the protein are both 
intracellular.
The Jka/Jkb polymorphism is defined by three single 
nucleotide polymorphisms (SNPs). An SNP is a variation at 
a single nucleotide position in the DNA. The antigen-defining 
SNP occurs in exon 9 at nucleotide position 838.17 At this 
position, the JK*01(JK*A) allele contains nt838G and encodes 
for aspartic acid at position 280; JK*02 (JK*B) contains nt838A, 
encoding for asparagine at this position. The p.Asp280Arg 
substitution is found in the fourth extracellular loop of the JK 
glycoprotein. The other two SNPs, which cause no change in 
the amino acid sequence, are at position 588 of exon 7 and 
position –46 in intron 9. The JK*01 allele is characterized 
by nt588a and IVS9-46a. The JK*02 allele contains nt588g, 
IVS9-46g. These changes are summarized in Figure 2. The 
molecular basis of In(Jk) and Jk3 remain unknown, although 
the In(Jk) suppressor is not linked to the JK locus.8
Sequencing studies have identified a number of molecular 
variations that result in the Jk(a–b–) phenotype. These 
changes occur on both the JK*01 and JK*02 alleles and 
affect the normal expression through exon deletions, intron 
changes that cause splice site mutations, and nucleotide 
substitutions. Most variants are, in fact, SNPs in the gene’s 
coding region that lead to missense mutations or premature 
stop codons. Two genetic variants are responsible for the 
majority of Jk(a–b–) phenotypes. The more frequent variant 
is found in the Polynesian population and has been assigned 
the allele designation JK*02N.01. At position –1 of intron 5 of 
the JK*02 allele, a G>A nucleotide substitution (c.342-1G>A) 
causes a splice site mutation that leads to the skipping of 
exon 6.11 The resulting truncated protein is not transported to 
the RBC membrane. In addition to Polynesians, this genetic 
variant has been reported in Vietnamese,18 Chinese,19,20 Thai, 
Filipino, and Indonesian21 individuals—suggesting a historical 
relationship between these groups. One Jk(a–b–) Asian Indian 
individual possesses the same 342-1G>A SNP, although it was 
found on the background of a JK*01 allele (nt838G).22
The second most frequent Jk(a–b–) genetic variant occurs 
in the Finnish population. A nucleotide substitution c.871T>C 
on a JK*02 background results in a serine to proline change 
at amino acid position 21.7 Other null variants have been 
Fig. 1. Depiction of JK glycoprotein in RBC membrane. Features 
include ten membrane spanning regions, five extracellular loops, 
glycosylation site on third extracellular loop, epitopes of Jka and 
Jkb in the fourth extracellular loop, and intracellular N-terminus and 
C-terminus.
Fig. 2. Arrangement of JK showing the JK*01/JK*02 polymorphisms. 
Open rectangles are non-coding exons.  Shaded rectangles are 
coding exons. Arrowhead indicates the missense substitution in 
exon 9 defining the JK polymorphism. The two remaining changes 
are silent.
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identified in single probands or in a small number of families. 
The Jk(a–b–) genetic variants are summarized in Table 2 
based on the International Society of Blood Transfusion 
(ISBT)-assigned allele name. Of interest are the variants 
identified in African American and Asian Indian individuals, 
since these groups have not historically been associated with 
the JKnull phenotype. A JK*01 allele with c.561C>A change 
was described by Horn et al. that illustrates the variation in 
frequency in different population groups of African descent.25 
The original propositus was an African American individual, 
but no additional examples of this variant were identified 
in testing of an additional 1000 African American blood 
donors. In contrast, the c.561C>A SNP was identified in 7 
of 1174 Brazilian blacks (1:164)6 who were heterozygous for 
Table 2. JKnull alleles
Allele name†
Exon (intron) 
location Nucleotide change Amino acid change Ethnic group
JK antibody 
produced‡ Reference(s)
JK*01N.01 Del 4 & 5 c.1-?_341+ ?del Initiation Met absent, 
exons 4–5 skipped
English, Tunisian, Bosnian -Jk3 Irshaid et al.,23 Lucien 
et al.,24 Wester et al.18
JK*01N.02 5 c.202C>T p.Gln68Ter Caucasian -Jk3 Wester et al.18 
JK*01N.03 7 c.582C>G p.Try194Ter Swiss -Jk3 Irshaid et al.23
JK*01N.04 10 c.956C>T p.Thr319Met African American None Wester et al.18  
JK*01N.05 7 c.561C>A p.Tyr187Ter African American, Brazilian 
black
-Jk3 Horn et al.25 
JK*01N.06 Intron 5 c.342-1G>A p.(Arg114_Thr156del), 
exon 6 skipped
Asian Indian -Jk3 Ekman et al.22 
JK*01N.07 8 c.723delA Ile262Ter Not reported -Jka Crews et al.26 
JK*01N.08 9 c.866A>G Asn269Ser Not reported Not reported Moulds et al.27
JK*01N.09 4 c.27_50del Val10-Arg17del African American -Jka Burgos et al.28
JK*01N.10 Intron 8 c.811+5G>A p.Ala270fs, exon 8 
skipped
Chinese None Guo et al.29
JK*02N.01 Intron 5 c.342-1G>A p.(Arg114_Thr156del), 
exon 6 skipped
Polynesian, Vietnamese, 
Chinese, Thai, Filipino, 
Indonesian 
-Jk3 Lucien et al.,11 Irshaid 
et al.,12 Lui et al.,19 Yan 
et al.,20 Lin and Lung-
Chih21
JK*02N.02 Intron 5 c.342-1G>C p.(Arg114_Thr156del), 
exon 6 skipped
Chinese none Meng et al.30
JK*02N.03 5 c.222C>A p.Asn74Lys Chinese, Taiwanese not reported Lui et al.,19 Guo et al.29
JK*02N.04 Intron 7 c.663+1G>T Leu223fs, exon 7 
skipped
French not reported Lucien et al.11
JK*02N.05 8 c.723delA Ile262fs Hispanic none Wester et al.18
JK*02N.06 9 c.871T>C p.Ser291Pro Finnish -Jk3 Sidoux-Walter et al.,7 
Irshaid et al.12 
JK*02N.07 9 c.896G>A p.Gly299Glu Chinese not reported Lui et al.,19 Guo et al.29
JK*02N.08 10 c.956C>T p.Thr319Met Asian Indian, Pakistani -Jk3 Wester et al.18 
JK*02N.09 4  c.191G>T p.Arg64Gln African American -Jkb Billingsley et al.,31  
Gaur et al.32
JK*02N.10 4 c.194G>A p.Gly65Asp Not reported Not reported St-Louis et al.33
JK*02N.11 7 c.499A>G, 
c.512G>A
p.Met167Val, 
p.Trp171Ter
Chinese None Guo et al.29
JK*02N.12 6,7 c.437T>C, 
c.499A>G
p.Leu146Pro, 
p.Met167Val
Chinese None Guo et al.29
JK*02N13 7 c.499A>G, 
c.536C>G
p.Met167Val, 
p.Pro179Arg
Chinese None Guo et al.29
JK*01 or JK*02 designates the source allele.
†Allele name is assigned by International Society of Blood Transfusion (ISBT) Working Party on Blood Group Antigens.
‡JK antibodies identified in original or subsequent propositi as listed in one or more cited references.
Consult the ISBT Web site (www.isbtweb.org) or recent publications for newly described alleles.
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561C/A and 1 individual who was homozygous for 561A/A 
and typed Jk(a–b–). Another variant, c.191G>T in JK*02, has 
recently been reported in an African American population at a 
frequency of approximately 1:400.31
Genetic variations predicted to encode weak or partial 
antigen expression have also been identified. Investigations 
of the propositi were generally initiated when antigen-typing 
discrepancies were seen with various sources of antisera or the 
propositus had produced an apparent alloantibody to the JK 
antigen detected either by a serological typing or predicted by 
the genotype at nt838 (Jka or Jkb). The first allele reported was 
a c.130G>A substitution described by Wester et al. that led to 
a weakened expression of Jka.34 Variant alleles are listed in 
Table 3. The antigens produced by these variant alleles would 
be termed partial following the convention of the D weak versus 
partial alleles. Until alloantibody production demonstrates 
that a glycoprotein produced is structurally different from the 
commonly found form, identified variants are considered to 
code for weaker than normal antigen expression.
Recognition of the relative likelihood of certain alternative 
alleles is important in designing JK genotyping assays. In 
addition to the c.838G>A polymorphism, assays should be 
designed to interrogate other regions of the JK gene where 
variations affecting antigen expression have been identified. 
This approach was used by Wester et al. to design a polymerase 
chain reaction multiplex screening assay to more effectively 
identify the genetic variants most commonly encountered 
in their investigations.38 For example, consideration of the 
c.561C>A variant or the c.191G>T variant would be important 
in screening assays for Brazilian or American blacks, 
respectively. Assays based on known SNPs, however, will 
not detect previously unknown genetic variations. When a 
screening test does not identify variant alleles, sequencing of 
exons 4–11 is required to avoid false results.
Function
The JK protein is expressed on RBCs and in the 
endothelium of the descending vasa recta and epithelial 
surfaces of the kidney inner medulla.39 In renal function, 
this transporter protein is important in regulating urea as 
part of the mechanism for urine concentration and water 
conservation.40 The erythrocyte JK glycoprotein serves to 
facilitate rapid urea transport across the RBC membrane.41 
This mechanism is thought to ensure red cell structural 
stability as the cells pass through the renal medulla via the 
vasa recta. Individuals of the Jk(a–b–) phenotype have been 
shown to have suboptimal urine concentrating ability.42 
Other than this deficit, no other clinical sequelae have been 
associated with the Jknull phenotype, suggesting the presence 
of compensatory mechanisms. The lack of urea transport in 
the RBCs is illustrated by the resistance of Jk(a–b–) RBCs to 
lysis in 2M urea.43 RBCs having normal JK phenotypes will 
lyse within 30 seconds as the urea is transported into the cells, 
followed by a rapid osmotic influx of water. Because of the lack 
of urea transport and therefore no water uptake, Jk(a–b–) cells 
remain intact after 2 minutes. This characteristic has been 
used to perform mass screening for Jk(a–b–) individuals.
The JK protein has also been isolated from human colon,44 
as well as brain, thymus, heart, lung, liver, small intestine, bone 
marrow, urinary tract, bladder, prostate, pancreas, skeletal 
muscle and spleen, and testes.45 The exact purpose of the urea 
transporters in non-erythroid, non-renal tissues remains 
speculative. No JK antigens have been found on lymphocytes, 
monocytes, granulocytes, or platelets.9
Table 3. JK partial or weak alleles
Allele name†
Exon (intron) 
location Nucleotide change Amino acid change Ethnic group
JK antibody 
produced‡ Reference(s)
JK*01W.01 4 c.130G>A p.Glu44Lys Caucasian, Asian, Chinese -Jkb; -Jk3 Wester et al.,34 
Whorley et al.35
JK*01W.02 7 c.551T>C p.Trp171Arg African American None Whorley et al.35 
JK*01W.03 4 c.28G>A p.Val10Met African American -Jka Deal et al.36
JK*01W.04 5 c.226G>A p.Val76Ile African American -Jka Deal et al.36
JK*01W.05 8 c.742G>A p.Ala248Thr American Indian Not reported Gaur et al.32  
JK*02W.01 7 c.548C>T p.Ala183Val African American None Whorley et al.35
JK*02W.02 8 c.718T>A p.Trp240Arg African American Not reported St-Louis et al.37
JK*01 or JK*02 designates the source allele.
†Allele name is assigned by International Society of Blood Transfusion (ISBT) Working Party on Blood Group Antigens.
‡JK antibodies identified in original or subsequent propositi as listed in one or more cited references.
Consult the ISBT Web site (www.isbtweb.org) or recent publications for newly described alleles.
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Antibodies
The antibodies to the three antigens of the JK system have 
been well documented in multiple studies and case reports as 
responsible for immediate and delayed transfusion reactions 
as well as HDFN.9 In contrast to the frequent severity of 
reactions to incompatible transfusion, cases of HDFN caused 
by Kidd antibodies are relatively mild.9 The antibodies are 
predominately caused by RBC stimulation, although the 
literature contains two examples of apparently naturally 
occurring anti-Jka.46,47 Most examples are IgG1 and IgG3, 
although some antibody examples can contain IgG2, IgG4, or 
IgM fractions.9
Anti-Jka and -Jkb are well known for their rapid and 
significant drop in titer to levels that are difficult to detect by 
routine serological methods. Double-dose Jk(a+) or Jk(b+) 
test cells or enzyme-treated cells may be necessary to detect 
weak antibody reactivity. Some Kidd antibodies can only be 
detected in antiglobulin tests in which serum and polyspecific 
antihuman globulin are used to detect complement binding.9 
In other reported examples, manual hexadimethrine bromide 
(polybrene) or solid-phase tests were required to detect 
reactivity of anti-Jka.9,26 If Kidd antibodies are not detected, 
the subsequent transfusion of antigen-positive RBCs results in 
a rapid anamnestic response, with the rising titer frequently 
resulting in a delayed transfusion reaction. Studies at the 
Mayo Clinic showed that 29 percent of the delayed hemolytic 
or delayed serologic transfusion reactions between August 
1999 and June 2007 involved JK system antibodies. The 
overwhelming majority of these were attributable to anti-Jka.48 
The severe immediate or delayed hemolytic transfusion 
reactions described with JK system antibodies were thought to 
be caused by the complement binding of IgG class antibodies. 
This was refuted, however, in studies by Yates et al. that 
demonstrated complement binding was only present in those 
antibodies that had a direct agglutinating component or were 
reactive in indirect antiglobulin tests using anti-IgM.49
Multiple examples of JK autoantibodies have been 
reported in the literature. The case reports show that the 
majority have had autoanti-Jka specificity and have presented 
with immune hemolysis.50–54 In many cases, an underlying 
autoimmune disease was present. Autoanti-Jkb and autoanti-
Jk3 are also reported.55,56 One report described an autoanti-
Jka that appeared during a course of methyldopa therapy.57 
The literature also contains descriptions of JK autoantibodies 
whose reactivity required the presence of paraben compounds 
found in commercial low-ionic-strength saline reagents,58,59 
were apparent autoantibodies with mimicking specificity,60 
and were transient antibodies produced during JK antigen 
suppression.61 It is interesting to postulate that some previously 
reported immune autoantibodies may have been caused by 
unrecognized variant Jka or Jkb on the RBCs of individuals 
whose RBCs type as antigen-positive. Reactivity with 
autologous cells in these cases might have been a temporary 
finding as the immune system refined the specificity of the 
alloantibody.
In a study examining genetic factors influencing JK 
immunization, Reviron et al. demonstrated that HLA-
DRB1*0101, -DRB1*0102, and -DRB1*1001 alleles were more 
frequently found in individuals immunized to Jka than in the 
non-immunized southern European population studied (65% 
versus 19.5%).62
Role in Renal Transplantation
Location of the JK antigens on renal cells raises intriguing 
questions about the impact of Kidd system antibodies on renal 
graft survival in kidney transplants. Several case reports 
suggest a role for this. Hamilton et al., Holt et al., and Rourk 
et al. report cases of cadaveric transplants to patients with 
negative antibody screens. Two to ten years after transplant 
and during a period where each patient was noncompliant 
with immunosuppressive regimes, acute graft rejection 
occurred simultaneously with the appearance of a Kidd system 
antibody.62–66 One case reported by Holt et al. described a 
patient who suffered a hemolytic reaction attributable to 
anti-Jka following a post-transplant transfusion.66 This was 
then followed by hyperacute rejection of the transplanted 
organ. In two cases where previous exposure to foreign 
RBCs had occurred, the appearance of the JK antibodies 
was presumed to be an anamnestic response. In the one case 
with no apparent RBC stimulation,64 the antigen-positive 
transplanted organ was postulated as providing the primary 
immunization stimulus. Nevertheless, even with prior RBC 
stimulus, primary immunization by the transplanted kidney 
should not be excluded.65 Leure et al. demonstrated in 370 
kidney transplants that mismatch of the recipient/graft at the 
JK locus was associated with a higher frequency of interstitial 
inflammation observed on kidney biopsy when compared 
with those recipient/graft pairs that were matched at the JK 
locus although overall graft survival was not influenced.67
Summary
Although recognized at the serological level in its most 
basic form for many decades, the Kidd blood group system 
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has been shown to be increasingly complex. The knowledge 
of this system has increased as the tools for investigating 
both phenotypic and genotypic variation have expanded. 
Future studies would be expected to result in a more complete 
understanding of the products of the variant alleles that are 
currently known as well as provide new information on the 
basis of Jk3 and In(Jk) phenotype. What remains unchanged 
is the clinical significance of Kidd system antibodies and the 
importance of recognizing them in order to provide safe blood 
components for transfusion.
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